Skip to main content

Tweets

Cluster analysis in axSpA pts classified 2 groups (predominantly axial vs peripheral dz) and showed lower TNFi drug survival rates in those with prominent extra-axial manifestations. Abs 0365 #ACR21 #RheumNow @RheumNow https://t.co/ArgQ7mNqeD https://t.co/XqF7rPneMV
Dr. Rachel Tate @uptoTate ( View Tweet )
4 years 9 months ago
🔥 Ready for the next level of imaging? The radio-labelled tracer binding to integrin αvβ3 99mTc-maraciclatide is able to detect hypervascularization in RA joints and correlates w/ PDUS findings ⭐️ Sens 78% ⭐️ See 91% Fancy, yet more invasive than US! #Abst0174 @RheumNow #ACR21 https://t.co/eCOxjJsERh
Aurelie Najm @AurelieRheumo ( View Tweet )
4 years 9 months ago
3/4 axSpA EMAS pts had/perceived to have employment challenge. Poor physical/mental health, lower education, hx job change due to axSpA associated w/difficulties/perceived difficulties. Earlier dx/rx AND advocacy needed. Abs 0366 #ACR21 #RheumNow @RheumNow https://t.co/dlGhOymxVQ https://t.co/CWD6U1vRE0
Dr. Rachel Tate @uptoTate ( View Tweet )
4 years 9 months ago
#ACR21 Previews from Creaky Joints https://t.co/9T3EepV3CE https://t.co/Ay0A3hWSxU
Dr. John Cush @RheumNow ( View Tweet )
4 years 9 months ago
Danish axSpA study shows pts in remission on TNFi may be able to taper and remain in remission at the 2 year mark. Abs0364 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/LBR5cSThQY https://t.co/sCqqhuBaTS
Dr. Rachel Tate @uptoTate ( View Tweet )
4 years 9 months ago
Gender differences in AS pts? IL-23R, IL-12R, IL-6R, JAK, STAT and TYK2 ⬇️regulated in men Small study of 20 pts, but could it guide targeted therapy based on gender?🤔 Abs#0050 https://t.co/OQHQCCzfuC #ACR21 @RheumNow

Robert B Chao, MD @doctorRBC ( View Tweet )

4 years 9 months ago
Dr Adachi presents ⬆️BMD gain with denosumab than risedronate in RA. Non-significant reduction in fractures (very small numbers) Interesting, but need to see fracture benefit in larger study to justify dmab as first line Abstr#0445 #ACR21 @RheumNow https://t.co/GgaS9JZGzb
Richard Conway @RichardPAConway ( View Tweet )
4 years 9 months ago
"I don't want rheumatologist only use BLMB and nephrologist using only VCS." - Dr. M Petri on how we should work together with nephrologists on managing lupus nephritis. (She did give a final dig & added "BLMB can be used with any GFR") #ACR21 #GreatDebate @rheumnow

TheDaoIndex @KDAO2011 ( View Tweet )

4 years 9 months ago
What's the added value of MRI in diagnosing #rheumatoidarthritis among pts w/ undiff'd arthritis? Accdg to this study by N. Hollander et al, Tenosynovitis was independently assoc'd w/ RA development esp. among ACPA- UA pts 👇 @RheumNow #ACR21 abs0155 https://t.co/F6xlZ1Hy7u
4 years 9 months ago
Don't forget to discuss Influenza vaccination w/ your RA patients! Higher concerns about RA medications and low necessity of vaccination beliefs associated with a ⬇️ likelihood of vaccination and suboptimal vaccine coverage. #ACR21 @RheumNow #Abst0141 https://t.co/c5GthZxh3n https://t.co/4Nt92CHFzV
Aurelie Najm @AurelieRheumo ( View Tweet )
4 years 9 months ago
#GreatDebate: add on BLMB vs. VCS to MMF for LN Dr. Petri argues for BLMB b/c: 👉cost is less 👉better adherance 👉not good for class V 👉voclosporin had greater nephrotoxicity 👉insuff data in pregnancy, but not contraindicated like VSC #ACR21 @rheumnow https://t.co/mk2eXwkxcG
TheDaoIndex @KDAO2011 ( View Tweet )
4 years 9 months ago
#ACR21 Great Debate Dr. Brad Rovin: Voclosporin: Combo with MMF is effective pts of diverse racial and ethnic backgrounds. ⭐️Big plus for a disease with large healthcare disparity issues @Rheumnow https://t.co/rMpCRPLLGQ
Eric Dein @ericdeinmd ( View Tweet )
4 years 9 months ago
×